GlassScriptPhysician profile
Swathi Rao
NPI 1154594133
$5,885.42
in general payments reported to CMS, 2019-2025
34 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $894 · 2022: $962 · 2023: $1,451 · 2024: $1,271 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.47 |
| Education | $133.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,248.92 | 2021-2025 | |
| Novo Nordisk INC | $906.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $774.25 | 2021-2025 | Freestyle Libre 3, Xience Skypoint, Pressurewire |
| Lilly USA, LLC | $250.86 | 2021-2025 | Mounjaro, Zepbound |
| Alexion Pharmaceuticals, INC. | $244.69 | 2022-2025 | Strensiq |
| Corcept Therapeutics | $158.24 | 2024-2025 | Korlym |
| Nestle Healthcare Nutrition INC. | $133.26 | 2021-2023 | |
| Astellas Pharma US INC | $125.67 | 2025 | Veozah |
| Exact Sciences Corporation | $92.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neos Therapeutics, LP | $83.32 | 2022-2025 | Adzenys Xr-Odt |
| Pfizer INC. | $73.82 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $72.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.38 | 2022 | |
| Ironshore Pharmaceuticals INC. | $57.55 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $51.80 | 2024-2025 | Unithroid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.95 | 2021-2023 | Xifaxan |
| Ibsa Pharma INC. | $44.23 | 2022-2024 | Tirosint, Licart, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $41.89 | 2021-2023 | Trintellix |
| Hologic Sales and Service, LLC | $40.57 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $38.81 | 2024 | Voquezna |
| Abiomed | $37.21 | 2025 | |
| Acella Pharmaceuticals, LLC | $32.89 | 2022-2023 | NP Thyroid 60 |
| Scynexis, INC. | $30.73 | 2022 | |
| Azurity Pharmaceuticals, INC. | $28.04 | 2023 | Adthyza |
| Paratek Pharmaceuticals, INC. | $27.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.16 | 2024 | Farxiga |
| Glaxosmithkline, LLC. | $24.78 | 2023 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $23.71 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $22.16 | 2023 | Loreev Xr, Gralise |
| Chiesi USA, INC. | $20.02 | 2024 | Mycapssa |
| Amgen INC. | $16.36 | 2025 | Repatha, Otezla |
| Shield Therapeutics INC | $15.86 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2021 | |
| Adlon Therapeutics L.P. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.